Quintanrix (diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed))
- Region
- 🇪🇺 EU
- Active substance
- diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Withdrawn
- Therapeutic area
- Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Diphtheria
- EU approval
- Thu 17 Feb 2005
- Application
- EMEA/H/C/000556
- ATC
- J07CA10
- Official record
- www.ema.europa.eu
Indication
Quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis B and invasive disease caused by Haemophilus influenzae type b and for booster immunisation of young children during the second year of life.The use of Quintanrix should be determined on the basis of official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Infanrix Hexa Authorised · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Hexacima Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Hexyon Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Vaxelis Authorised · MCM Vaccine B.V.
- 🇪🇺 Tritanrix HepB Lapsed · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Infanrix Penta Lapsed · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Hexavac Withdrawn · Sanofi Pasteur MSD, SNC
- 🇪🇺 Infanrix HepB Withdrawn · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Triacelluvax Withdrawn · Chiron S.p.A.
- 🇪🇺 Primavax Withdrawn · Pasteur Mà¨rieux MSD
Follow Quintanrix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.